FF Pharma Overview

  • Founded
  • 2012
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

FF Pharma General Information


Developer of an anti-CD40 monoclonal antibody therapy intended to offer treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn's disease. The company's anti-CD40 monoclonal antibody therapy is a negative allosteric modulator of the CD40 pathway and functions as a reversible switch for B cell activation and inhibits immune responses, enabling doctors to offer treatment for chronic inflammatory and autoimmune diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Primary Office
  • Yalelaan 46
  • 3584 CM Utrecht
  • Netherlands
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

FF Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Sep-2016 00.000 Completed Out of Business
1. Early Stage VC (Series A) 23-Jan-2013 00.000 00.000 Completed Startup
To view FF Pharma’s complete valuation and funding history, request access »

FF Pharma Executive Team (6)

Name Title Board Seat Contact Info
Mark De Boer Ph.D Co-Founder & Chief Executive Officer
Ton Adang Ph.D Chief Operating Officer
Louis Boon Ph.D Co-Founder & Chief Scientific Officer
Cornelis Wortel Ph.D Chief Medical Officer
You’re viewing 4 of 6 executive team members. Get the full list »

FF Pharma Board Members (4)

Name Representing Role Since
Bram Vanparys Ph.D PMV Supervisory Board Member 000 0000
Kevin Johnson Ph.D Index Ventures Board Member 000 0000
Stéphane Verdood Vesalius Biocapital Partners Supervisory Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »